🚀 VC round data is live in beta, check it out!
LTR Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for LTR Pharma and similar public comparables like Dicot Pharma, Türk İlaç, TScan Therapeutics, Mereo BioPharma Group and more.
LTR Pharma Overview
About LTR Pharma
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men’s health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
Founded
2020
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$40M
LTR Pharma Financials
LTR Pharma reported last fiscal year revenue of $100K and negative EBITDA of ($4M).
In the same fiscal year, LTR Pharma generated $100K in gross profit, ($4M) in EBITDA losses, and had net loss of ($4M).
LTR Pharma P&L
In the most recent fiscal year, LTR Pharma reported revenue of $100K and EBITDA of ($4M).
LTR Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $100K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $100K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 100% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($4M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (3835%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (5124%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($4M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (3837%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
LTR Pharma Stock Performance
LTR Pharma has current market cap of $62M, and enterprise value of $40M.
Market Cap Evolution
LTR Pharma's stock price is $0.34.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $40M | $62M | -0.3% | XXX | XXX | XXX | $-0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLTR Pharma Valuation Multiples
LTR Pharma trades at 399.0x EV/Revenue multiple, and (10.4x) EV/EBITDA.
LTR Pharma Financial Valuation Multiples
As of April 8, 2026, LTR Pharma has market cap of $62M and EV of $40M.
Equity research analysts estimate LTR Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
LTR Pharma has a P/E ratio of (16.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $62M | XXX | $62M | XXX | XXX | XXX |
| EV (current) | $40M | XXX | $40M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 399.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (10.4x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (7.8x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 399.0x | XXX | XXX | XXX |
| P/E | — | XXX | (16.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (13.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified LTR Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
LTR Pharma Margins & Growth Rates
LTR Pharma's revenue in the last fiscal year grew by 0%.
LTR Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (3835%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (11%) | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2535% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1912% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 5224% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
LTR Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Dicot Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Türk İlaç | XXX | XXX | XXX | XXX | XXX | XXX |
| TScan Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mereo BioPharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Instil Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
LTR Pharma M&A Activity
LTR Pharma acquired XXX companies to date.
Last acquisition by LTR Pharma was on XXXXXXXX, XXXXX. LTR Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by LTR Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLTR Pharma Investment Activity
LTR Pharma invested in XXX companies to date.
LTR Pharma made its latest investment on XXXXXXXX, XXXXX. LTR Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by LTR Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout LTR Pharma
| When was LTR Pharma founded? | LTR Pharma was founded in 2020. |
| Where is LTR Pharma headquartered? | LTR Pharma is headquartered in Australia. |
| Is LTR Pharma publicly listed? | Yes, LTR Pharma is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of LTR Pharma? | LTR Pharma trades under LTP ticker. |
| When did LTR Pharma go public? | LTR Pharma went public in 2023. |
| Who are competitors of LTR Pharma? | LTR Pharma main competitors are Dicot Pharma, Türk İlaç, TScan Therapeutics, Mereo BioPharma Group. |
| What is the current market cap of LTR Pharma? | LTR Pharma's current market cap is $62M. |
| What is the current revenue of LTR Pharma? | LTR Pharma's last fiscal year revenue is $100K. |
| What is the current EV/Revenue multiple of LTR Pharma? | Current revenue multiple of LTR Pharma is 399.0x. |
| Is LTR Pharma profitable? | No, LTR Pharma is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.